CRISPR - International Biopharmaceutical Industry

news

RNA Editing: Emerging from CRISPR’s Shadow

Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start. Thor...

4 November 2024 news CRISPR | RNA Editing

Continue Reading →

news

Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird’s crucial year

The biggest industry news of the week came not from the J.P. Morgan Healthcare Conference or any associated announcements, but from Washington, D.C, where the Centers...

14 January 2022 news Alzheimer | blood

Continue Reading →

news

Vertex aligns with another CRISPR gene editing startup

Mammoth's evolution into a drugmaker appears to be paying off. Three years ago, the company formed with a plan to use CRISPR gene editing to detect and diagnose dise...

29 October 2021 news CRISPR | drugmaker

Continue Reading →

news

Lilly joins RNA editing race with ProQR deal

Much of the attention in the genetic editing world in recent years has been on CRISPR and the "genetic scissors" that allow researchers to make targeted changes to DN...

10 September 2021 news CRISPR | genetic editing

Continue Reading →

Volume 4 Issue 3

CRISPR-Cas9 Knockout Screening Using Primary Human Cells in Drug Discovery

While significant progress has been made carrying out CRISPR screens in immortalised cell lines, a more physiological and clinically relevant alternative is human pri...

31 August 2021 Volume 4 Issue 3 CRISPR | development

Continue Reading →

news

Vertex, CRISPR gene-editing therapy hit with clinical hold

U.S. regulators have placed a clinical hold on CRISPR Therapeutics' lead candidate, spurring a double-digit drop in the Swiss biotech's stock value by Thursday mo...

1 June 2018 news clinical | CRISPR

Continue Reading →